Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.

Kwara A, Yang H, Antwi S, Enimil A, Gillani FS, Dompreh A, Ortsin A, Opoku T, Bosomtwe D, Sarfo A, Wiesner L, Norman J, Alghamdi WA, Langaee T, Peloquin CA, Court MH, Greenblatt DJ.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01657-18. doi: 10.1128/AAC.01657-18. Print 2019 Jan.

2.

Evaluation of the Adequacy of WHO Revised Dosages of the First-Line Antituberculosis Drugs in Children with Tuberculosis Using Population Pharmacokinetic Modeling and Simulations.

Horita Y, Alsultan A, Kwara A, Antwi S, Enimil A, Ortsin A, Dompreh A, Yang H, Wiesner L, Peloquin CA.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00008-18. doi: 10.1128/AAC.00008-18. Print 2018 Sep.

PMID:
29914960
3.

Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children.

Yang H, Enimil A, Gillani FS, Antwi S, Dompreh A, Ortsin A, Adu Awhireng E, Owusu M, Wiesner L, Peloquin CA, Kwara A.

Pediatr Infect Dis J. 2018 Jan;37(1):43-51. doi: 10.1097/INF.0000000000001687.

4.

Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection.

Kwara A, Enimil A, Gillani FS, Yang H, Sarfo AM, Dompreh A, Ortsin A, Osei-Tutu L, Kwarteng Owusu S, Wiesner L, Norman J, Kurpewski J, Peloquin CA, Ansong D, Antwi S.

J Pediatric Infect Dis Soc. 2016 Dec;5(4):356-365. Epub 2015 May 26.

Supplemental Content

Loading ...
Support Center